MedElevator
Войти в исследования International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025
Alternative dosing regimen of magnesium sulfate for prevention of eclampsia: An observational prospective study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
To Anh M, Nguyen Minh H N, Nguyen Tri C, Bui Trung Q, Dao Yen T H, Le Thanh V, Ngo Thao V, Pham Toan D, Ho Tuong M, Vuong Lan N
Аннотация
OBJECTIVE: To evaluate serum magnesium concentrations in pregnant women with severe pre-eclampsia being treated with a novel magnesium sulfate regimen for seizure prevention.
METHODS: This was a prospective, longitudinal study. Pregnant women aged 18 years or older with severe pre-eclampsia and an indication for treatment with magnesium sulfate were included. Participants received a magnesium sulfate loading dose of 4.5 g over 20 min, then a maintenance dose of 1.5 g/h (the standard regimen at the study center). Serum magnesium concentrations were measured at admission, 30 min, 1, 2, 4, and 6 h, then every 6 h until treatment was stopped. Median (interquartile range [IQR]) serum magnesium concentrations are reported. The primary outcome was serum magnesium concentrations during magnesium sulfate infusion.
RESULTS: Serum magnesium concentrations at admission and after 30 min were 0.77 (IQR 0.72-0.82) and 1.81 (IQR 1.63-1.97) mmol/L, respectively. After 4 h, the concentration had decreased slightly to 1.79 (IQR 1.58-2.02) mmol/L. By 12 h, magnesium levels had stabilized at 2 mmol/L. At this time, 50.9% (28/55) had achieved therapeutic magnesium levels (2.0-3.5 mmol/L), and this proportion had increased to 61.7% (29/47) by 24 h. Magnesium toxicity was observed in three patients (4.7%). No cases of eclampsia or maternal mortality were recorded.
CONCLUSIONS: This magnesium sulfate regimen was generally well tolerated and also prevented seizures even though serum magnesium levels at 24 h were below the currently defined therapeutic range in at least one-third of participants.
METHODS: This was a prospective, longitudinal study. Pregnant women aged 18 years or older with severe pre-eclampsia and an indication for treatment with magnesium sulfate were included. Participants received a magnesium sulfate loading dose of 4.5 g over 20 min, then a maintenance dose of 1.5 g/h (the standard regimen at the study center). Serum magnesium concentrations were measured at admission, 30 min, 1, 2, 4, and 6 h, then every 6 h until treatment was stopped. Median (interquartile range [IQR]) serum magnesium concentrations are reported. The primary outcome was serum magnesium concentrations during magnesium sulfate infusion.
RESULTS: Serum magnesium concentrations at admission and after 30 min were 0.77 (IQR 0.72-0.82) and 1.81 (IQR 1.63-1.97) mmol/L, respectively. After 4 h, the concentration had decreased slightly to 1.79 (IQR 1.58-2.02) mmol/L. By 12 h, magnesium levels had stabilized at 2 mmol/L. At this time, 50.9% (28/55) had achieved therapeutic magnesium levels (2.0-3.5 mmol/L), and this proportion had increased to 61.7% (29/47) by 24 h. Magnesium toxicity was observed in three patients (4.7%). No cases of eclampsia or maternal mortality were recorded.
CONCLUSIONS: This magnesium sulfate regimen was generally well tolerated and also prevented seizures even though serum magnesium levels at 24 h were below the currently defined therapeutic range in at least one-third of participants.